ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Online GLP-1 Medication Program For Weight Loss: Personalized Treatment Launched

OrderlyMeds has announced that it is accepting more patients into its online weight loss program, making GLP-1 injections more accessible.

-- OrderlyMeds has announced that it is accepting more patients into its online weight loss programs, which are offered as a convenient alternative to in-person treatments.

For more information, please visit https://orderlymeds.com/

The GLP-1 hormone is released by the small intestine when food passes through the digestive system. This hormone triggers insulin release from the pancreas, blocks the secretion of glucagon, and slows the emptying of the stomach so less glucose is released from food into the bloodstream - effects that all play a role in lowering blood sugar levels after eating. Additionally, GLP-1 affects areas of the brain that process hunger, prolonging feelings of satiety and keeping individuals fuller for longer.

As OrderlyMeds explains, glucagon-like peptide-1 agonists, commonly abbreviated to GLP-1 agonists, are a class of medications, usually injectable, that mimic these effects. They are most often prescribed to regulate blood sugar levels in individuals with type 2 diabetes, but more recently, they have been used to manage unhealthy weight gain and obesity due to their ability to suppress appetite. GLP-1 medications are also approved for use in many weight loss treatments, including the ones that OrderlyMeds offers.

Individuals who enroll in OrderlyMeds’ programs will receive a personalized GLP-1 treatment plan developed based on a detailed evaluation of their health history by a licensed medical provider. Possible options include Wegovy and Zepbound, but compounded GLP-1 and GLP-1/GIP medications are also available; these medications are more cost-effective than their brand-name alternatives, but they will only be prescribed when it is deemed medically appropriate by the patient’s physician.

Regardless of the choice, medications will be shipped to the customer’s address, ensuring they can complete treatment from the comfort of their home. For the first three months, the medication dosage will be increased steadily as the patient’s body adjusts; the next three months will focus on integrating lifestyle changes, including dietary adjustments and physical activity recommendations. After six months, patients will be given the opportunity to evaluate their progress and adjust their weight loss goals, and beyond month 10, treatment focus will shift to sustaining whole-body health over the long term.

More information is available at https://orderlymeds.com/

Contact Info:
Name: Annie Dawson
Email: Send Email
Organization: OrderlyMeds
Address: 235 Ponce De Leon Pl Suite M347, Decatur, Georgia 30030, United States
Website: https://orderlymeds.com/

Source: PressCable

Release ID: 89185484

If you come across any problems, discrepancies, or concerns related to the content contained within this press release that necessitate action or if a press release requires takedown, we strongly encourage you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will be readily accessible round-the-clock to address your concerns within 8 hours and take appropriate actions to rectify identified issues or support with press release removals. Ensuring accurate and reliable information remains our unwavering commitment.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  207.59
-2.55 (-1.21%)
AAPL  252.10
+0.61 (0.24%)
AMD  202.62
-0.06 (-0.03%)
BAC  47.62
+0.10 (0.21%)
GOOG  295.44
-3.58 (-1.20%)
META  594.76
-9.30 (-1.54%)
MSFT  375.33
-7.67 (-2.00%)
NVDA  174.81
-0.82 (-0.47%)
ORCL  149.06
-5.28 (-3.42%)
TSLA  384.34
+3.49 (0.92%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.